Cardio-Oncology

New Cancer Patients

Cancer care saves lives. However, there is mounting evidence that many cancer therapies may cause cardiotoxicity–a condition that damages the heart. As a result, new cancer patients and survivors may be at an increased risk of developing cardiovascular disease.

MyoStrain® provides actionable information to help cardio-oncologists proactively detect and manage the cardiotoxic effects of cancer therapy on the heart without interrupting cancer care. Physicians may be able to use this approach to determine cardio-protective treatment strategies, optimize the effectiveness of protective treatment, and monitor the patient’s heart health throughout cancer therapy.

Cancer Survivors

There are 17 million cancer survivors in the United States, may of whom may not currently be monitored for cardiotoxicity. 1 in 10 of these patients will experience an adverse cardiac event, and cancer recurrence is 59% more likely in patients with cardiovascular disease. This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.

MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.

Cancer Survivors

There are 17 million cancer survivors in the United States, may of whom may not currently be monitored for cardiotoxicity. 1 in 10 of these patients will experience an adverse cardiac event, and cancer recurrence is 59% more likely in patients with cardiovascular disease. This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.

MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.

Cancer Survivors

There are 17 million cancer survivors in the United States, may of whom may not currently be monitored for cardiotoxicity. 1 in 10 of these patients will experience an adverse cardiac event, and cancer recurrence is 59% more likely in patients with cardiovascular disease. This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.

MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019